Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat

Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat

Introduction and Objectives: Metabolic associated fatty liver disease (MAFLD) is characterized by hepatic steatosis with the following three metabolic conditions: obesity/overweight, diabetes and metabolic dysregulation, either alone or in combination. Pirfenidone (PFD) has anti-inflammatory, antiox...

Full description

Bibliographic Details
Main Authors:	J. Gutiérrez-Cuevas, D López-Cifuentes, AS Sandoval-Rodríguez, AO Vázquez-Esqueda, JS Rodríguez-Sanabria, J Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268122002022

Similar Items

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel
by: Daniel López-Cifuentes, et al.
Published: (2024-02-01)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2021-06-01)

The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH
by: JS Rodriguez Sanabria, et al.
Published: (2022-12-01)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Ana Sandoval-Rodriguez, et al.
Published: (2022-04-01)

Prolonged-release pirfenidone decreases hepatic miRNAs expression in a NAFLD/NASH experimental model
by: R. Escutia-Gutiérrez, et al.
Published: (2020-09-01)

Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model
by: J. Gutiérrez-Cuevas, et al.
Published: (2020-09-01)

Effect of methyl donor supplementation on gut microbiota and hepatic expression of key miRNAs in a murine model of MAFLD
by: Rebeca Rosas-Campos, et al.
Published: (2024-02-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

MexMix supplementation prevented MAFLD development by restoring microbiota-gut-liver axis in a mice model.
by: Rebeca Rosas-Campos, et al.
Published: (2024-02-01)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-10-01)

The gut microbiota and key parameters associated with MAFLD are modified by MEXMIX
by: R Rosas-Campos, et al.
Published: (2022-12-01)

<i>Moringa oleifera</i> Improves MAFLD by Inducing Epigenetic Modifications
by: C. Alejandra Monraz-Méndez, et al.
Published: (2022-10-01)

Molecular, histological and biochemical changes in a NASH murine model whit a diet high in fats and sugars
by: J.S. Rodríguez Sanabria, et al.
Published: (2020-09-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model
by: J.A. Silva-Gómez, et al.
Published: (2020-09-01)

Role of Insulin Resistance in MAFLD
by: Yoshitaka Sakurai, et al.
Published: (2021-04-01)

Pirfenidone regulates antioxidant response via NRF2 in an experimental model of hepatocellular carcinoma
by: HC Monroy-Ramírez, et al.
Published: (2022-12-01)

P- 43 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

O-24 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

Dietary supplementation with methyl donors improves physiopathological conditions of NAFLD in a murine model
by: A Vazquez Esqueda, et al.
Published: (2022-12-01)

Ameliorative effects of pirfenidone in chronic kidney disease
by: Samad Ghodrati, et al.
Published: (2022-07-01)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01)

An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease
by: J. Samael Rodríguez-Sanabria, et al.
Published: (2022-01-01)

Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2024-02-01)

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
by: Simón A. Ojeda-Duran, et al.
Published: (2020-05-01)

Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 line
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
by: Jorge Antonio Silva-Gomez, et al.
Published: (2021-10-01)

Pirfenidone ameliorates alcohol-induced promotion of breast cancer in mice
by: Hui Li, et al.
Published: (2024-03-01)

Garlic (Allium sativum) polysaccharides ameliorates hepatic injury and fat accumulation in mice with metabolic associated fatty liver disease (MAFLD)
by: Jie Liu, et al.
Published: (2022-12-01)

Exploring the metabolic and molecular benefits of methyl donor supplementation in a model of metabolic and fatty liver disease
by: Angel Vazquez-Esqueda, et al.
Published: (2024-02-01)

Moringa oleifera decreases biomarkers of oxidative stress in a murine NASH model
by: A Monraz-Méndez, et al.
Published: (2022-12-01)

Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria
by: Yufang Liu, et al.
Published: (2024-02-01)

Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
by: Hugo C. Monroy-Ramírez, et al.
Published: (2024-02-01)

Stimulatory action of cycloheximide on glucose metabolism in the rat epididymal fat pad
by: J A García-Sáinz, et al.
Published: (1977-01-01)

Correlation between serum uric acid and body fat distribution in patients with MAFLD
by: Min Tao, et al.
Published: (2023-09-01)

Gender differences in the ideal cutoffs of visceral fat area for predicting MAFLD in China
by: Pingping Yu, et al.
Published: (2022-12-01)

Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease
by: Lin Hai Kurahara, et al.
Published: (2018-01-01)

Methyl-group donor supplementation beneficial effects on metabolic, histological, and inflammatory parameters in a murine model of alcoholic steatohepatitis
by: Carolina Diaz-Canul, et al.
Published: (2024-02-01)

Restoring skeletal muscle mass as an independent determinant of liver fat deposition improvement in MAFLD
by: Ting Zhou, et al.
Published: (2023-12-01)